Business Wire

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow and maximize opportunities of its iron portfolio.

“In support of our ambitious growth strategy, optimizing our manufacturing footprint will enable us to build an even stronger, more efficient organization focusing on core capabilities in nephrology, and to maximize and leverage our market-leading expertise and intellectual property in iron deficiency,” commented Abbas Hussain, CEO of Vifor Pharma. “With CordenPharma, we have found the best suitable solution for our manufacturing employees and the drug production activities in Fribourg, Ettingen and Lisbon. With this agreement, Vifor Pharma is well positioned to continuously drive the company sustainably and profitably over the long term, for all our stakeholders.”

Dr. Michael Quirmbach, Chief Executive Officer & President of CordenPharma said: “The acquired Vifor Pharma sites have competent teams with great cultural fit, state-of-the art infrastructure, and a strong compliance track record. This excellent opportunity aligns well with our strategy to broaden our CDMO capabilities. By incorporating these three Vifor Pharma manufacturing facilities into our global network, we look forward to not only supplying Vifor Pharma as a manufacturing partner, but also closing gaps in our service offering for oral solid dosage drug product manufacturing and increasing our overall capacity. In addition, this acquisition further strengthens our fully-integrated solutions to our customers.”

Under the terms of the signed share purchase agreement, CordenPharma acquires all shares in Vifor SA, Fribourg (including its Ettingen branch), and OM Pharma SA, Lisbon, thus taking over Vifor Pharma’s finished drug product manufacturing operations at the three sites. The divestment will trigger an asset impairment, to be reported with Vifor Pharma’s 2021 financial results. The companies have agreed not to disclose financial terms of the agreement.

CordenPharma will integrate the new facilities into its existing CDMO network of Current Good Manufacturing Practice (cGMP) and R&D plants across Europe & the US, and organize the operations of the Fribourg, Ettingen and Lisbon sites under its Small Molecule Platform. It plans to utilize the existing manufacturing workforce, while continuing to produce and supply Vifor Pharma products. Vifor Pharma’s Swiss and Portuguese country commercial organizations, located in Fribourg and Lisbon, will remain with Vifor Pharma Group. Vifor Pharma and CordenPharma will jointly ensure long-term continuity of supply for customers and patients who depend on them.

This divestment, including all financial implications, has been disclosed to CSL Limited in the course of the due diligence process preceding the publication of the pre-announcement of the public tender offer by CSL Limited on 14 December and in so far has no impact on such tender offer.

Vifor Pharma and CordenPharma anticipate closing the transaction in Q1 2022, contingent on customary closing conditions.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

About CordenPharma
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Excipients, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under five Technology Platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma experts translate complex processes and projects at any stage of development into high-value products.

For more information about CordenPharma, contact us or visit cordenpharma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

CordenPharma:
Dr. Stephen Houldsworth
VP, Global Head of Platform Management & Marketing
Stephen.Houldsworth@cordenpharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DNP Accelerates Development of Photomask Manufacturing Process for 2nm Generation EUV Lithography27.3.2024 01:23:00 CET | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has begun development of a photomask manufacturing for 2-nanometer (10-9 meter) generation logic semiconductors that support Extreme Ultra-Violet (EUV) lithography, the cutting-edge process for semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319148117/en/ Image of EUV lithography with pellicle, a protective film for the photomask (Photo: Business Wire) DNP will also act as a subcontractor and provide the newly developed technology to Tokyo-based Rapidus Corporation (Rapidus). Rapidus is participating in the Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems instigated by the New Energy and Industrial Technology Development Organization (NEDO). [Background] We have strengthened our ability to manufacture cutting-edge semiconductors with high productivity and quality. And in 2016, DNP

NTT Communications: Digital Event Connects Tokyo and Kanazawa via World's Longest IOWN APN to Commemorate Hokuriku Shinkansen Line's Extension27.3.2024 01:00:00 CET | Press release

NTT Communications Corporation (NTT Com) and the Hokuriku Regional Office of NTT DOCOMO, INC. (DOCOMO), together with the city of Kanazawa, celebrated the opening of a new section of the Hokuriku Shinkansen Line between Kanazawa and Tsuruga by holding digital events on March 16 under the theme of "Connection," a key component of NTT Group’s Innovative Optical and Wireless Network (IOWN) concept.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325762257/en/ Scheme of live remote performance (Graphic: Business Wire) The events included a live remote performance that seamlessly connected musicians in Kanazawa and Tokyo, a distance of about 1,000 kilometers, via the All-Photonics Network (APN). For the connection, NTT Com provided its APN Leased Line Plan powered by IOWN,2 which used the longest optical cable ever deployed in an IOWN demonstration and the first to be deployed in Japan's Hokuriku region. The event brought toge

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting27.3.2024 00:07:00 CET | Press release

Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave the Board on June 26, 2024 upon the expiration of his term. Candidates for Directors Who Are Not Audit and Supervisory Committee Members Name Category Expected Role Christophe Weber Internal Existing Representative Director, President & Chief Executive Officer Andrew Plump Internal Existing Director, Pr

Ekran System Presents Exclusive Webinar: Insider Threat Management Best Practices for NIS2 Compliance26.3.2024 23:53:00 CET | Press release

Ekran System is thrilled to announce its upcoming webinar dedicated to Insider Threat Management Best Practices for NIS2 Compliance, scheduled for March 28. This highly anticipated event will provide invaluable insights into fortifying organizational defenses against insider threats while ensuring compliance with NIS2 regulations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326790482/en/ Insider Threat Management Best Practices for NIS2 Compliance Webinar by Ekran System (Graphic: Business Wire) Participants will have the opportunity to: Explore Insider Threat Management Best Practices for Zero Trust Security and Cyber Hygiene Learn about Best Practices for Supply Chain Security and Human Resources Discover Tools for Incident Handling and Reporting Gain insights from a Real-life Case Study detailing a global manufacturer's journey towards NIS2 Compliance with insider threat management tools Understand the Benefits of u

Trustfull Appoints Jim Greenwell as Executive Advisor26.3.2024 21:19:00 CET | Press release

Trustfull, a leading risktech platform utilizing silent checks on phone, email, IP address, and device intelligence to combat fraud across onboarding, authentication, and payments, announces the appointment of Jim Greenwell as Executive Advisor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326786868/en/ Jim Greenwell (Photo: Business Wire) Greenwell joins the company with deep experience in the digital identity and mobility space, most recently serving as an executive adviser to Thomson Reuters and AuthenticID, as well as serving on the advisory boards of Prove and Gravy Analytics. Jim is the former CEO of Danal, Inc., having led the company’s growth and innovation within the mobile identity and authentication space for over a decade through its sale to Boku, Inc. (LON: BOKU) in 2019. During his tenure, Jim created successful global partnerships and enduring customer relationships in a broad range of industries, includi

HiddenA line styled icon from Orion Icon Library.Eye